The GLP-3 question, briefly
GLP-2 TZ is GLP-1 plus GIP. GLP-3 RT adds glucagon. Why the receptor count matters for in-vitro work, and why the literature is still catching up.
The shorthand has gotten ahead of the science. “GLP-3” isn’t a receptor. It’s an informal label for the next generation of incretin agonists — molecules that bind more than two receptors at once. Here’s what’s actually happening at the receptor level, and why it matters for receptor-binding studies.
Three receptors, one molecule
The original GLP-1 receptor agonists (GLP-1 SM-class molecules, liraglutide, exenatide) bind a single receptor: the glucagon-like peptide 1 receptor. They’re mono-agonists, and the receptor selectivity is well-characterized.
GLP-2 TZ is a dual agonist. It binds two receptors:
- GLP-1R (glucagon-like peptide 1 receptor)
- GIPR (glucose-dependent insulinotropic polypeptide receptor)
GLP-3 RT goes further. It binds three:
- GLP-1R
- GIPR
- GCGR (glucagon receptor)
The informal “GLP-3” label refers to this tri-agonist class — molecules engaging the third receptor (glucagon) on top of the GLP-1 and GIP targets. There is no “GLP-3 receptor.”
Why the receptor count matters in the dish
For receptor-binding studies, mono-agonists give clean receptor-binding curves: one binding site, one competition curve, one Hill coefficient. Multi-agonists don’t.
A tri-agonist like GLP-3 RT will show three different binding affinities depending on which receptor cell line you run the assay on:
| Receptor | Approx. Kd (in-vitro) | Relative potency |
|---|---|---|
| GLP-1R | ~0.07 nM | 1.0× (reference) |
| GIPR | ~0.20 nM | 0.35× |
| GCGR | ~1.7 nM | 0.04× |
Approximate values from published in-vitro binding assays. Real numbers vary by cell line, expression level, and tracer.
The biological signal isn’t the average of those three potencies. It’s the integrated activation of three pathways at once, which is non-linear and dose-dependent. A simple EC50 against one receptor will systematically misrepresent the molecule.
What this means for your assay design
If you’re characterizing a tri-agonist, consider:
- Run all three receptor binding assays separately — GLP-1R, GIPR, GCGR — on cell lines expressing each receptor in isolation. Don’t try to extract all three from a multi-receptor cell.
- Use a labeled tracer specific to each receptor, not a generic radioligand.
- Report the three Kd values independently, not as a composite.
- For functional assays, cAMP accumulation downstream of each receptor responds at different timescales — capture early (≤15 min) and late (60+ min) timepoints.
The literature gap
Most published binding data on GLP-2 TZ- and GLP-3 RT-class molecules comes from the developing companies’ own in-vitro panels. Independent replication is sparse, and the cell lines, tracers, and research applications vary enough that the numbers aren’t directly comparable across studies. The field will catch up; it hasn’t yet.
For now, treat any single published Kd value as a starting point, not a measured ground truth. The molecule’s behavior depends on the receptor you’re looking at and how you’re looking at it.